Alector disclosed that its GSK‑partnered antibody failed to meet co‑primary clinical endpoints in a Phase III dementia trial. The negative outcome prompted the company to stop development of the asset and initiate a workforce reduction of roughly half the staff. Management said the decision will realign R&D focus and reduce operating costs while it reassesses strategic priorities and collaborations.